Dual Antiplatelet Therapy

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Dual Antiplatelet Therapy is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

9/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Completed18 · 42%

Unknown status9 · 21%

Recruiting9 · 21%

Terminated3 · 7%

Active, not recruiting2 · 5%

Not yet recruiting1 · 2%

Other1 · 2%

Clinical Trials

Trial Activity

43 trials

Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study

Recruiting·UUniversity of Florida·Phase 4·NCT06821191·78 enrolled

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

Recruiting·FFondazione Ricerca e Innovazione Cardiovascolare ETS·N/A·NCT06535568·576 enrolled

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Recruiting·UUniversity of Florida·Phase 4·NCT06691191·48 enrolled

Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy

Recruiting·—·Phase 3·NCT05952206·2,312 enrolled

Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)

Recruiting·UUniversity of Florida·Phase 4·NCT07025148·40 enrolled

OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina

Recruiting·KKorea University Guro Hospital·N/A·NCT07198529·130 enrolled

Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG

Recruiting·KKexiang Liu, MD·N/A·NCT06981390·300 enrolled

A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge

Recruiting·—·N/A·NCT06301776·560 enrolled

Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients

Recruiting·—·N/A·NCT06276374·1,556 enrolled

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study

Active, not recruiting·KKyoto University, Graduate School of Medicine·Phase 4·NCT04609111·6,002 enrolled

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS

Active, not recruiting·KKyoto University, Graduate School of Medicine·Phase 4·NCT03462498·3,008 enrolled

Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients

Not yet recruiting·UUniversity Medical Center Ho Chi Minh City (UMC)·N/A·NCT06648720·3,566 enrolled

The Dual Antiplatelet Therapy Study (DAPT Study)

Completed·BBaim Institute for Clinical Research·Phase 4·NCT00977938·25,682 enrolled

Nobori Dual Antiplatelet Therapy as Appropriate Duration

Completed·AAssociations for Establishment of Evidence in Interventions·Phase 4·NCT01514227·3,773 enrolled

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

Completed·KKyoto University, Graduate School of Medicine·Phase 4·NCT02619760·3,045 enrolled

Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)